Targeting CDK7/9 and casein kinase 1 alpha as a therapeutic strategy in advanced-stage uveal melanoma

Uveal melanoma (UM) patients frequently develop advanced-stage disease in the liver, but treatment options are limited. The low tumor mutation burden and the transcriptional rewiring observed in aggressive, BRCA1-associated protein 1 (BAP1)-deficient UM led us to investigate transcriptional-based inhibitors in preclinical models. Drug screening data and analysis of the Dependency Map (DepMap) indicated that UM cell lines exhibit a strong dependency on the transcriptional cyclin-dependent kinases, 7 and 9 (CDK7/9). Treatment of BAP1-deficient UM cell lines with SY-5609, a CDK7 inhibitor, led to growth inhibition associated with stalled cell cycle progression. Casein kinase 1 alpha (CK1α) is highly expressed in BAP1-deficient UM patient tumors and treatment of BAP1-deficient UM cell lines with A51, a CDK7/9 plus CK1α inhibitor led to both cell cycle arrest and induction of cell death. RNA-sequencing and protein array analysis associated A51 effects with down-regulation of the pro-survival protein, MCL1. Depletion of MCL1 enhanced cell death in SY-5609-treated UM cells, whereas overexpression of MCL1 rescued cell death in A51-treated UM cells. In a non-invasive in vivo liver injection model of UM tumor growth, A51 reduced tumor onset and improved overall survival. Overall, these studies show that A51 causes cell death in advanced-stage UM preclinical models, at least in part, through down-regulating MCL1.

Authors

Institutions

Publication Details

Journal
Molecular Cancer Therapeutics
Published
2026-11-17
DOI
https://doi.org/10.1158/1535-7163.mct-26-0850
Primary Topic
Ocular Oncology and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeting CDK7/9 and casein kinase 1 alpha as a therapeutic strategy in advanced-stage uveal melanoma

Inna Chervoneva, Jorge Silvio Gutkind, Eric Hung, Michael A. Davies et al.
1 links
Molecular Cancer Therapeutics
Ocular Oncology and Treatments
article

Targeting CDK7/9 and casein kinase 1 alpha as a therapeutic strategy in advanced-stage uveal melanoma

Inna Chervoneva, Jorge Silvio Gutkind, Eric Hung, Michael A. Davies, Irit Snir-Alkalay, Vivian Y.L. Chua, Corinne E. Wessner, Andrew E. Aplin, John Robert Eisenbrey, Ji‐Bin Liu, Yinon Ben‐Neriah, Timothy J. Purwin, Jelan I. Haj, Francis J. Waltrich
article en

Abstract

Uveal melanoma (UM) patients frequently develop advanced-stage disease in the liver, but treatment options are limited. The low tumor mutation burden and the transcriptional rewiring observed in aggressive, BRCA1-associated protein 1 (BAP1)-deficient UM led us to investigate transcriptional-based inhibitors in preclinical models. Drug screening data and analysis of the Dependency Map (DepMap) indicated that UM cell lines exhibit a strong dependency on the transcriptional cyclin-dependent kinases, 7 and 9 (CDK7/9). Treatment of BAP1-deficient UM cell lines with SY-5609, a CDK7 inhibitor, led to growth inhibition associated with stalled cell cycle progression. Casein kinase 1 alpha (CK1α) is highly expressed in BAP1-deficient UM patient tumors and treatment of BAP1-deficient UM cell lines with A51, a CDK7/9 plus CK1α inhibitor led to both cell cycle arrest and induction of cell death. RNA-sequencing and protein array analysis associated A51 effects with down-regulation of the pro-survival protein, MCL1. Depletion of MCL1 enhanced cell death in SY-5609-treated UM cells, whereas overexpression of MCL1 rescued cell death in A51-treated UM cells. In a non-invasive in vivo liver injection model of UM tumor growth, A51 reduced tumor onset and improved overall survival. Overall, these studies show that A51 causes cell death in advanced-stage UM preclinical models, at least in part, through down-regulating MCL1.

Molecular Cancer Therapeutics
The University of Texas MD Anderson Cancer Center (US), Thomas Jefferson University (US), Hebrew University of Jerusalem (IL), Hadassah Medical Center (IL), University of California San Diego (US)
Good health and well-being
Ocular Oncology and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon